Please ensure Javascript is enabled for purposes of website accessibility
Cory Renauer

Cory Renauer

TMFang4apples

Cory is a long-term minded analyst focused on the Healthcare Sector. He genuinely enjoys cutting through the complexity to help everyday investors make better decisions.

Recent articles

life-science-professionals

Is Galapagos Stock a Bad-News Buy Right Now?

Despite some serious setbacks, this beaten-down biotech could be a terrific bargain at recent prices.


another-smiling-scientist-getty

3 Reasons Rigel Pharmaceuticals Stock Can Continue Soaring

Here's why this stock's big run-up in recent months could be just the beginning.


life-science-getty

Johnson & Johnson's COVID-19 Vaccine Inventory Is Lighter Than Expected

If authorized for emergency use later this month, the White House expects just a few million doses of Johnson & Johnson's coronavirus vaccine candidate in its inventory by the end of February.


Team-of-healthcare-professionals-getty

3 Top Healthcare Stocks to Buy Now

Find out how shares of these disruptive businesses could make you rich.


life-sciences-work-getty

3 Reasons to Buy Ocular Therapeutix Stock Right Now

There are a few reasons this could be the best biotech stock you can buy at the moment.

life-science-pro-making-selection-getty

Is Ocugen a Buy After Doubling Last Week?

This company's coronavirus vaccine partner took some big steps forward.


dissapointed-investor-computer-getty

Gilead Sciences and Galapagos Shutter Their Pulmonary Fibrosis Program

Despite solid signs of efficacy in mid-stage trials, the partners are shutting down all clinical trials with ziritaxestat.


smiling-scientist-laboratory-getty

Can KalVista Pharmaceuticals Stock Fly Higher?

Can this under-the-radar biotech and its hereditary angioedema candidate produce more gains for investors?


scientist-microscope-getty

Should You Sell Cassava Sciences Stock Now?

Can this company's Alzheimer's disease candidate deliver further gains ahead?


Here_s_Why_Investors_Should_Remember_These_2_Healthcare_Lessons_in_2021

Here's Why Investors Should Remember These 2 Healthcare Lessons in 2021

If you're thinking about investing in healthcare stocks this year, remember these two things.

The_Scariest_Part_of_Intuitive_Surgical_s_Latest_Earnings_Call

The Scariest Part of Intuitive Surgical's Latest Earnings Call

Here's why shares of the surgical robotics company have been under pressure.


1_Big_Problem_in_Johnson_&_Johnson_s_Latest_Earnings_Call

1 Big Problem in Johnson & Johnson's Latest Earnings Call

The coronavirus pandemic continues to pressure one of the company's big operating segments.


2_Green_Flags_for_Abbott_Labs_and_1_Red_Flag

2 Green Flags for Abbott Labs and 1 Red Flag

Coronavirus testing won't last forever, but the future still looks bright for Abbott Labs.


Is_Abbott_Labs_a_Good_Stock_to_Buy_Now

Is Abbott Labs a Good Stock to Buy Now?

Luckily, coronavirus tests aren't this company's only rising source of revenue.


2_Green_Flags_in_Intuitive_Surgical_s_Q4_Earnings

2 Green Flags in Intuitive Surgical's Q4 Earnings

Despite a tough year, there were two big sources of encouragement from the surgical robotics leader.

2_Green_Flags_In_Johnson_&_Johnson_s_Latest_Earnings_Report

2 Green Flags in Johnson & Johnson's Latest Earnings Report

Strong pharmaceutical sales and an impressive growth forecast gave investors reasons to smile.


Here_s_Why_Novavax_Can_Beat_Johnson_&_Johnson_in_the_COVID-19_Vaccine_Race

Here's Why Novavax Can Beat Johnson & Johnson in the COVID-19 Vaccine Race

Johnson & Johnson's coronavirus vaccine offers one-shot convenience, but Novavax has clear advantages.


scientist-looking-at-stuff-getty

Here's Why Pfizer's a Great Stock to Buy and Hold Now

Around $15 billion from coronavirus vaccine sales this year will be just the beginning.


smiling-doctors-getty

5 Reasons to Buy Clover Health Stock Right Now

After decades of effort, electronic health records could finally get an upgrade that allows them to work as intended.


group-of-smiling-doctors-getty

Coronavirus Vaccine From Novavax Is 89.3% Effective

Results of a U.K. study suggest that an easy-to-distribute COVID-19 vaccine from Novavax is effective against the new variant.